RBC Capital analyst Ashish Sabadra raised the firm’s price target on CME Group (CME) to $302 from $295 and keeps a Sector Perform rating on the shares. The firm cites the company having published its Clearing and Transaction net pricing increases of about 1% this week, alleviating investor concerns and signaling plans for strategic pricing increases throughout the year rather than the traditional December increases, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CME:
- CME Group price target raised to $266 from $262 at JPMorgan
- CME Group price target raised to $328 from $305 at TD Cowen
- CME Group price target raised to $340 from $319 at Morgan Stanley
- CME Group: Resilient Fee-Based Franchise with Defensive Strengths and Underappreciated Structural Growth Justifies Buy Rating
- CME Group price target raised to $312 from $304 at Barclays